Haven't had much time lately? Here's what you may have missed in the last few months
New in 2015: Hairy Cell Leukaemia, Myeloproliferative Neoplasms, Thymic Epithelial Tumours, Central Venous Access, Treatment of Dyspnoea
02 Oct 2015
Shoulder function impairment is linked to the use of adjuvant treatment for head and neck cancer
02 Oct 2015
The editors have included topics including the emerging processes of evading tumour destruction and tumour inflammation, new challenges posed by tumour...
01 Oct 2015
Actionable mutations can be detected in small lung cancer biopsy samples using next-generation sequencing
30 Sep 2015
Nivolumab is superior to docetaxel for overall survival after 18 months of follow-up in patients with nonsquamous non-small-cell lung cancer
29 Sep 2015
Brain metastases show clinically actionable genetic differences from their primary tumours
J. Taieb elaborates clinical perspective of new players in mCRC therapeutic arena. Molecular analysis from the RECOURSE study, showed that TAS-102 is equally effective in KRAS mutant and wild-type tumours. Conclusions for BRAF subset cannot be drawn due to small numbers. TAS-102 reverse 5-FU activity and it is well tolerated in heavily pretreated patients. Further, he elaborates the QoL data from the RAISE study of FOLFIRI plus ramucirumab, a Monoclonal antibody directed against VEGFR2 after first-line therapy with bevacizumab in mCRC.